https://nanoporetech.com/resource-centre/accelerating-precision-oncology-research-with-nanopore-sequencing
Native, PCR-free nanopore sequencing, with unrestricted read lengths, offers a unique view into cancer biology. This allows the identification of single nucleotide variants, structural variants, and epigenetic modifications on a haplotype level — from a single dataset. In this symposium, we explored how these technical benefits open up a new

https://www.youtube.com/watch?v=wy0sdbjeC-g
Native, PCR-free nanopore sequencing, with unrestricted read lengths, offers a unique view into cancer biology, identifying single nucleotide variants, struc

https://nanoporetech.com/about/events/conferences/aacr-2024
Accelerating precision oncology research with nanopore sequencing. Date: Monday, April 8th, 2024. Time: 12:30 PM - 1:30 PM PT. Location: Spotlight Theater B. ... Telomere dynamics in aging and cancer by nanopore long-read sequencing. Time: 9:00 am - 12:30 pm. Location: Section 13, 1639 / 9.

https://www.nature.com/articles/s41598-023-29550-8
In cancer research, MinION-based nanopore sequencing has been successfully employed for mutation detection 3,4,5, DNA methylome analysis 6,7,8, DNA copy number profiling 7,9, and the

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333861/
Clinical research on cancer. In the era of precision oncology, the development of molecular target drugs allows for the identification of specific tumor types based on genomic changes and the administration of matching therapies. 305 Comprehensive assessment of a tumor patient's genome through sequencing can guide clinical treatment based on

https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-and-oxford-nanopore-announce-collaboration-to-advance-precision-medicine-for-cancer-and-genetic-disorders/
Nanopore sequencing is well positioned to serve Mayo Clinic's goals of improving testing in some of the hardest-to-characterize conditions. The ability to sequence any-length fragments of DNA — from short to long and ultra-long — and examine methylation in real time offers the potential to provide clinicians with a more complete picture

https://www.nature.com/articles/s41565-023-01462-8
Our strategy will be readily transferable to nanopore sequencing ... ratcheting of DNA in a nanopore at 5-Å precision. ... that receives its core funding from Cancer Research UK (FC001002), the

https://www.biorxiv.org/content/biorxiv/early/2022/05/31/2022.05.31.494109.full.pdf
Transcriptome profiling is a mainstay of translational cancer research and is increasingly finding its way into precision oncology. While bulk RNA sequencing (RNA-seq) is widely available, high costs and long data return time are limiting factors for clinical applications. We investigated a portable nanopore long-read sequencing device (MinION

https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10027
10027 Background: The real-time nature of nanopore sequencing allows for simultaneous basecalling of DNA sequences during sequencing. This unique capability enables adaptive sampling (AS), a software-controlled targeted sequencing method. AS is notable for its ability to rapidly and flexibly enrich multiple genes with long fragment reads and detect various modalities of genetic aberrations in

https://academic.oup.com/clinchem/advance-article-abstract/doi/10.1093/clinchem/hvae041/7642942
Nanopore sequencing for RNA and DNA has had a profound impact on scientific research in human genomics. Long-read, single-molecule sequencing, coupled with a small physical footprint, low cost of operation, and real-time data generation, has the potential for far-reaching clinical applications.

https://www.biorxiv.org/content/10.1101/2022.05.31.494109v1
Transcriptome profiling is a mainstay of translational cancer research and is increasingly finding its way into precision oncology. While bulk RNA sequencing (RNA-seq) is widely available, high costs and long data return time are limiting factors for clinical applications. We investigated a portable nanopore long-read sequencing device (MinION, Oxford Nanopore Technologies) for transcriptome

https://nanoporetech.com/accelerating-cancer-research-through-comprehensive-genomic-analysis
Overview. In this white paper, you will learn how cancer researchers are using nanopore sequencing to overcome the key challenges associated with short-read sequencing technologies to deliver: More compete and contiguous cancer genome assemblies. Accurate resolution of structural variants and repeat regions.

https://pubmed.ncbi.nlm.nih.gov/37724303/
Furthermore, we discuss the impact of the newly developed nanopore direct RNA sequencing (RNA-Seq) approach in advancing epitranscriptome research in cancer. Although the unique challenges still present for these new single-molecule long-read methods, they will unravel many aspects of cancer genome complexity in unprecedented ways and present

https://oxfordnanoporedx.com/resource-centre
Accelerating precision oncology research with nanopore sequencing. Cancer research; Human genomics; Methylation; Epigenetics; June 11 2024. Browse all resources. Brochure. Brochure: biopharma — cell and gene therapies. January 17 2024. Case study. The potential of nanopore cell-free RNA sequencing for earlier cancer detection.

https://www.degruyter.com/document/doi/10.1515/mr-2021-0013/html?lang=en
In the past several years, nanopore sequencing technology from Oxford Nanopore Technologies (ONT) and single-molecule real-time (SMRT) sequencing technology from Pacific BioSciences (PacBio) have become available to researchers and are currently being tested for cancer research. These methods offer many advantages over most widely used high-throughput short-read sequencing approaches and allow

https://www.thejcdp.com/doi/JCDP/pdf/10.5005/jp-journals-10024-3240
The advent of the novel nanopore sequencing technique has the potential to detect the alterations at the genomic level. This review highlights nanopore sequencing, its advantages and disadvantages, and how research supports its application in the field of oral oncology. Materials and methods: Web-based search via PubMed database, internet

https://link.springer.com/article/10.1007/s12033-024-01213-7
Nanopore Sequencing and Haplotype Phasing. On average, we sequenced 820 reads per sample, with an average length of 813 bp, which correspond to 60.9% of the length of the PCR product (i.e., 1336 bp) (Table 2).A large proportion of the reads (> 98%) were mapped to the genomic reference sequence of the GSTA1 promoter region (Table 2).We show in Fig. 1 an example of mapping for the sequencing

https://nuprobe.com/2021/09/nuprobe-technology-enables-rapid-ultrasensitive-mutation-detection-on-nanopore-platforms/
HOUSTON, Sept. 6, 2021 — NuProbe scientists and collaborators recently published a new method for sensitive detection of somatic mutations using Oxford Nanopore sequencing platforms. The method, termed oncogene concatenated enriched amplicon nanopore sequencing (OCEANS), enables rapid, accurate, and affordable detection of somatic mutations as low as 0.05% variant allele frequency (VAF).

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911782/
Transcriptome profiling is a mainstay of translational cancer research and is increasingly finding its way into precision oncology. While bulk RNA sequencing (RNA-seq) is widely available, high investment costs and long data return time are limiting factors for clinical applications. We investigated a portable nanopore long-read sequencing

https://oxfordnanoporedx.com/resource-centre/nanopore-sequencing-and-its-clinical-applications
Nanopore sequencing is a method for determining the order and modifications of DNA/RNA nucleotides by detecting the electric current variations when DNA/RNA oligonucleotides pass through the nanometer-sized hole (nanopore). Nanopore-based DNA analysis techniques have been commercialized by Oxford Nanopore Technologies, NabSys, and Sequenom, and

https://nanoporetech.com/news/american-association-of-cancer-research-oxford-nanopore-showcases-transformative-technology-for-accelerating-oncology-research
Meet our team of experts in booth #3053 and mark your calendars for our Spotlight Theatre presentations on Monday, 8th April at 12:30 PM PT. Oxford Nanopore Technologies are looking forward to joining the cancer research community at this year's American Association of Cancer Research (AACR) conference in San Diego, April 5th - 10th.

https://www.nature.com/articles/s41578-024-00695-w
Development of novel therapies for central nervous system (CNS) disorders has experienced a high failure rate in clinical trials owing to unsatisfactory efficacy and adverse effects. One of the

https://source.wustl.edu/2024/06/washu-medicine-launches-center-for-translational-bioinformatics/
Washington University School of Medicine in St. Louis is launching a Center for Translational Bioinformatics, an innovative joint effort of the university's McDonnell Genome Institute and the Institute for Informatics, Data Science & Biostatistics.The center will bring together experts from diverse fields to accelerate precision medicine research and improve patient care by integrating

https://nanoporetech.com/ja/resource-centre/accelerating-precision-oncology-research-with-nanopore-sequencing
Native, PCR-free nanopore sequencing, with unrestricted read lengths, offers a unique view into cancer biology. Login / Register . Sites. Community. Events. EPI2ME. Oxford Nanopore Technologies Fully scalable, real-time DNA/RNA sequencing technology. Oxford Nanopore Diagnostics NCM 2024: Boston .

https://www.nature.com/articles/s41576-024-00746-6
Metagenomic studies provide interesting insights into the hidden diversity and functional potential of ecosystems; for example, such studies have added hundreds of thousands of new microbial